The United States is the global leader in developing innovative and life-saving cures and treatments thanks to the investments made by pharmaceutical companies in the United States, including the vaccines that helped end the coronavirus pandemic. Vaccines are crucial to the physical and economic health of not just Americans but also people across the rest […]
The 340B Drug Discount Program was given the laudable goal of helping federally funded clinics and public hospitals that serve a large uninsured population cover the cost of drugs and provide discounts to patients. However, like many other well-intended federal programs 340B has gone off the rails due to the lack of clear intent and […]
President Trump has made lowering drug prices and reducing healthcare costs for Americans a top priority of his second term, along with encouraging more biopharmaceutical investment and innovation in the U.S. Citizens Against Government Waste suggests that he can achieve both objectives without imposing price controls, which includes Most Favored Nation (MFN) polices, reforming the […]
Federal healthcare programs are often well-intended but end up costing more than expected and become subject to waste, fraud, abuse, and mismanagement. One of the best (or worst) examples of such a result is the 340B Drug Pricing Program, which is administered by the Health Resources and Services Administration (HRSA). The lack of clear intent […]
The federal 340B Drug Pricing Program was intended to provide discounts on drugs to patients but the lack of a clear intent and patient definition, along with inadequate oversight, has led to the program being exploited by hospitals and contract pharmacies to generate millions of dollars in profit. The discounts are supposed to be provided […]
President Trump has made government efficiency a top priority. These efforts include eliminating improper payments and ensuring that only those who are eligible for government programs receive the benefits, including Medicaid. As President Trump said on “Meet the Press” on Sunday, May 4, 2025, “if illegal immigrants are in the mix, if people that aren’t […]
USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
On January 5, 2024, the U.S. FDA authorized Florida’s drug importation program.
The use of march-in rights to steal intellectual property will neither lower costs nor create more access to healthcare.
